A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Software can be a medical device. Can it also be a drug?
Alcohol kills – and in this case, that could be a good thing.
Medtronic decides that Solitaire is best played with a partner.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.